AVADEL PHARMACEUTICALS PLCAVDLEarnings & Financial Report
Avadel Pharmaceuticals, is an Irish specialty pharmaceutical company that focuses on sleep disorder medicines. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
Revenue
$41.5M
Gross Profit
$38.7M
Operating Profit
$-12.7M
Net Profit
$-13.8M
Gross Margin
93.3%
Operating Margin
-30.7%
Net Margin
-33.3%
YoY Growth
2674.3%
EPS
$-0.14
AVADEL PHARMACEUTICALS PLC Q2 FY2024 Financial Summary
AVADEL PHARMACEUTICALS PLC reported revenue of $41.5M (up 2674.3% YoY) for Q2 FY2024, with a net profit of $-13.8M (up 78.5% YoY) (-33.3% margin). Cost of goods sold was $2.8M, operating expenses totaled $51.5M.
Key Financial Metrics
| Total Revenue | $41.5M |
|---|---|
| Net Profit | $-13.8M |
| Gross Margin | 93.3% |
| Operating Margin | -30.7% |
| Report Period | Q2 FY2024 |
AVADEL PHARMACEUTICALS PLC Annual Revenue by Year
AVADEL PHARMACEUTICALS PLC annual revenue history includes year-by-year totals (for example, 2024 revenue was $169.1M).
| Year | Annual Revenue |
|---|---|
| 2024 | $169.1M |
AVADEL PHARMACEUTICALS PLC Quarterly Revenue & Net Profit History
AVADEL PHARMACEUTICALS PLC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $77.5M | +54.9% | $20.0K | 0.0% |
| Q2 FY2025 | $68.1M | +64.2% | $9.7M | 14.2% |
| Q1 FY2025 | $52.5M | +93.2% | $-4.9M | -9.4% |
| Q4 FY2024 | $50.4M | +159.1% | $-5.0M | -10.0% |
| Q3 FY2024 | $50.0M | +613.2% | $-2.6M | -5.2% |
| Q2 FY2024 | $41.5M | +2674.3% | $-13.8M | -33.3% |
| Q1 FY2024 | $27.2M | — | $-27.3M | -100.6% |
| Q4 FY2023 | $19.5M | — | $-28.8M | -148.0% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $27.2M | $41.5M | $50.0M | $50.4M | $52.5M | $68.1M | $77.5M |
| YoY Growth | N/A | N/A | 2674.3% | 613.2% | 159.1% | 93.2% | 64.2% | 54.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $164.7M | $167.9M | $157.5M | $158.3M | $164.2M | $167.9M | $187.2M | $199.4M |
| Liabilities | $77.0M | $89.5M | $87.2M | $83.6M | $90.4M | $93.9M | $96.4M | $101.2M |
| Equity | $87.7M | $78.4M | $70.3M | $74.7M | $73.8M | $74.1M | $90.7M | $98.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-28.0M | $-29.7M | $-18.2M | $-6.9M | $7.9M | $-8.2M | $12.7M | $22.2M |